https://www.live-feeds.com/feed/az-s-r-d-chief-barr-touts-internal-science-success-story-after-il-33-antibody-s-stellar-showing-in-copdContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/az-s-r-d-chief-barr-touts-internal-science-success-story-after-il-33-antibody-s-stellar-showing-in-copdhttps://www.live-feeds.com/feed/az-s-r-d-chief-barr-touts-internal-science-success-story-after-il-33-antibody-s-stellar-showing-in-copd#u64505Fri, 11 Sep 2026 00:50:57 +0000AstraZeneca reports that its IL-33 antibody, tozorakimab, significantly reduced COPD exacerbations in the OBERON and TITANIA Phase III trials. The drug showed benefits across various patient groups, including current and former smokers. R&D chief Barr described the results as an internal science success story. The positive late-stage data strengthens the company's prospects for the drug to become a blockbuster treatment for chronic obstructive pulmonary disease.Why it mattersCOPD is a chronic inflammatory lung disease that often leads to sudden worsening of symptoms known as exacerbat